SBE13 joins the family of Polo-like kinase 1 (Plk1) inhibitors.
Liu
Xiaoqi
X
liu8@purdue.edu
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001596:Benzylamines / Q000494:pharmacology*; D002453:Cell Cycle / Q000187:drug effects; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors*; D045744:Cell Line, Tumor; D006801:Humans; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors*; D011725:Pyridines / Q000494:pharmacology*; D000097869:Polo-Like Kinase 1
D000970:Antineoplastic Agents; D001596:Benzylamines; D018797:Cell Cycle Proteins; D047428:Protein Kinase Inhibitors; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D011725:Pyridines; D000097869:Polo-Like Kinase 1; C549033:SBE13 compound